Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.

Vikas Srinivasan SridharFrancesco CosentinoSamuel Dagogo-JackDarren K McGuireRichard E PratleyNilo B CaterMargaret Noyes EssexJames P MancusoYujie ZhaoDavid Z I Cherney

Published in: Diabetes, obesity & metabolism (2024)

Ertugliflozin was generally associated with lowering UA overall and across subgroups compared with placebo, and numerically reduced rates of gout-related outcome events.

Keyphrases

uric acid
metabolic syndrome
cardiovascular disease
type diabetes
clinical trial
randomized controlled trial
cardiovascular risk factors
coronary artery disease
cardiovascular events
study protocol
weight loss